<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536092</url>
  </required_header>
  <id_info>
    <org_study_id>C-15-HR-03</org_study_id>
    <nct_id>NCT02536092</nct_id>
  </id_info>
  <brief_title>A Prospective Multi-Center Study of a Novel Dual-Wavelength Laser for Hair Removal</brief_title>
  <official_title>A Prospective Multi-Center Study of a Novel Dual-Wavelength Laser for Hair Removal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cutera Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cutera Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of the Cutera excel HR dual wavelength 755nm Alexandrite&#xD;
      and 1064nm Nd:YAG laser for hair removal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center prospective, open-label, uncontrolled multi-center study of up to 50&#xD;
      male or female subjects, age 18 to 65 years, who desire laser hair removal. Subjects will&#xD;
      receive 6 hair removal treatments, spaced 8 weeks apart, and will be followed at 12 weeks&#xD;
      post-final treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor terminated study&#xD;
  </why_stopped>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physician's Global Assessment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of hair reduction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse device effects</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessment of ADEs immediately following each laser treatment and at the final follow-up visit</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hypertrichosis</condition>
  <arm_group>
    <arm_group_label>755nm and 1064nm Nd:YAG laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>755nm and 1064nm Nd:YAG laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>755nm and 1064nm Nd:YAG laser</intervention_name>
    <description>Dual wavelength 755nm and 1064nm Nd:YAG laser</description>
    <arm_group_label>755nm and 1064nm Nd:YAG laser</arm_group_label>
    <other_name>Excel HR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female or Male, 18 to 65 years of age (inclusive).&#xD;
&#xD;
          -  Fitzpatrick Skin Type I - VI (Appendix 3).&#xD;
&#xD;
          -  Subject has black or dark brown unwanted hair.&#xD;
&#xD;
          -  Subject must be able to read, understand and sign the Informed Consent Form.&#xD;
&#xD;
          -  Must be willing and able to adhere to the treatment and follow-up schedule and&#xD;
             post-treatment care instructions.&#xD;
&#xD;
          -  Willing to refrain from shaving the treatment area for 5 days prior to each study&#xD;
             visit.&#xD;
&#xD;
          -  Willing to have digital photographs taken of the treatment area and agree to use of&#xD;
             photographs for presentation, educational or marketing purposes.&#xD;
&#xD;
          -  Must agree not to use hair removal products, such as topical chemical depilatories, or&#xD;
             undergo any other hair removal procedure during the study, such as other laser and&#xD;
             light therapies or waxing.&#xD;
&#xD;
          -  Willing to refrain from excess sun exposure and willing to wear sunscreen on the&#xD;
             treatment area during the study (including the follow-up period).&#xD;
&#xD;
          -  Be in good health, as determined by the Investigator.&#xD;
&#xD;
          -  Post-menopausal or surgically sterilized, or using a medically acceptable form of&#xD;
             birth control at least 3 months prior to enrollment and during the entire course of&#xD;
             the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in a clinical trial of another device or drug within 6 months prior to&#xD;
             enrollment or during the study.&#xD;
&#xD;
          -  Had any type of professional hair removal procedure, such as laser, light-based, RF or&#xD;
             electrolysis, in the treatment area within 12 months of study participation.&#xD;
&#xD;
          -  Had other epilation treatment, such as waxing or mechanical epilator, in the treatment&#xD;
             area within 6 months of study participation.&#xD;
&#xD;
          -  Subject shows signs of actinic bronzing or recent tanning in the treatment area, and&#xD;
             unable/unlikely to refrain from tanning during the study&#xD;
&#xD;
          -  History of malignant tumors in the target area.&#xD;
&#xD;
          -  Pregnant and/or breastfeeding.&#xD;
&#xD;
          -  Having an infection, dermatitis or a rash in the treatment area.&#xD;
&#xD;
          -  Significant concurrent illness, such as diabetes mellitus or cardiovascular disease,&#xD;
             e.g., uncontrolled hypertension.&#xD;
&#xD;
          -  Suffering from coagulation disorders or taking prescription anticoagulation&#xD;
             medications.&#xD;
&#xD;
          -  History of keloid scarring, hypertrophic scarring or of abnormal wound healing.&#xD;
&#xD;
          -  Currently using immunosuppressive medications or history of immunosuppression/immune&#xD;
             deficiency disorder, such as psoriasis, eczema, vitiligo, systemic lupus erythematosus&#xD;
             or scleroderma.&#xD;
&#xD;
          -  History of seizure disorders due to light.&#xD;
&#xD;
          -  Any use of medication that is known to increase sensitivity to light according to&#xD;
             Investigator's discretion.&#xD;
&#xD;
          -  History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes&#xD;
             zoster (shingles) in the treatment area, unless treatment is conducted following a&#xD;
             prophylactic regimen&#xD;
&#xD;
          -  History of radiation to the treatment area or undergoing systemic chemotherapy for the&#xD;
             treatment of cancer.&#xD;
&#xD;
          -  History of pigmentary disorders, particularly tendency for hyper- or&#xD;
             hypo-pigmentation.&#xD;
&#xD;
          -  Systemic use of corticosteroid or isotretinoin within 6 months of study participation.&#xD;
&#xD;
          -  Anytime in life, having have used gold therapy (gold salts) for disorders such as&#xD;
             rheumatologic disease or lupus.&#xD;
&#xD;
          -  Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning&#xD;
             during the study.&#xD;
&#xD;
          -  Current smoker or history of smoking within 6 months of study participation.&#xD;
&#xD;
          -  As per the Investigator's discretion, any physical or mental condition which might&#xD;
             make it unsafe for the subject to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lezara Laser &amp; Vein Care</name>
      <address>
        <city>Squamish</city>
        <state>British Columbia</state>
        <zip>V5B0C1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Body Bar Laser Clinic/Academy</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V4P1B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>August 27, 2015</study_first_submitted>
  <study_first_submitted_qc>August 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2015</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrichosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Study terminated</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

